Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

Completed · Not applicable

Conditions studied: Type 2 Diabetes

In brief

This study is a randomized, double-blind, placebo-controlled, dose-response study of BKR-017 and placebo that will be conducted at two investigative sites. The total duration of subject involvement is approximately 15 weeks; the screening period can be up to 3 weeks prior to the start of test period, followed by a 12-week test period. During the test period, subjects will self-administer three tablets of test product, two times daily: before breakfast and before bedtime.

Key facts

Study ID

NCT04673656

Run by

BioKier Inc.

People needed

60

Starts

2021-04-18

Expected to finish

2023-02-07

Last updated by the study team

2023-02-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females between the ages of 18 and 70 years at the time of screening, inclusive
• Diagnosed with T2D and under the care of a healthcare professional for its management, or newly diagnosed (as participant in the study) with T2D
• HbA1c 6.5% -10.5%, inclusive
• Has given written informed consent to participate in this study
• Willing to complete 84-day test period
• Willing to maintain current diet and exercise routine and current prescription medications for the duration of the study

You may not qualify if…

• Type 1 diabetes
• History of bariatric or intestinal surgery
• Active gastrointestinal disease including but not limited to irritable bowel syndrome, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), diverticulitis, gastroparesis
• Active and clinically significant hepatic, pancreatic disease, or renal disease as determined by the investigator
• History of heart disease that in the opinion of the investigator should exclude the subject from the study
• Severely uncontrolled hypertension at screening defined as a systolic blood pressure > 180 mmHg or a diastolic blood pressure > 110 mmHg on the average of two seated measurements after being at rest for at least 5 minutes
• Untreated or uncontrolled hyperthyroidism or hypothyroidism, or other significant thyroid disease
• Active significant infection as determined by the investigator
• Known allergy to butyrate or any of the components of the tablets
• Subjects planning to make major changes to diet and physical activity during the trial duration
• Participation in a clinical trial and/or treatment with an investigational drug during the 30 days before screening, or within 5 half-lives of receipt of an investigational drug or twice the duration of the biological effect of any investigational drug (whichever is longer)
• Pregnant, nursing, or trying to become pregnant
• In the investigator's judgment, the subject is not suitable for the study for any other reason or cannot commit to the requirements of the study.
• Subject is taking one or more of the excluded therapies.

Where it is running

• Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States
• Duke Clinical Research at Pickett Road — Durham, North Carolina, United States
• Duke Clinical & Translational Science Institute (CTSI) — Kannapolis, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.